Pharma BD Deal Intelligence
Headlined 'Mylan Inc. to Become a Women's Healthcare Powerhouse With $800 Million Buy'; notes Famy Care is the largest producer of generic oral contraceptives…
Bresch: 'In 2008, Mylan established a partnership with Famy Care, significantly enhancing its presence in the women's health care segment in the U.S. and other…
Mylan to acquire Famy Care women's health businesses for $750M cash plus up to $50M contingent payments, building vertically integrated platform with…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Mylan agreed to acquire certain women's healthcare businesses from Famy Care for $750M cash plus up to $50M contingent payments. Famy Care was the world's largest producer of generic OCPs. Acquisition closed November 20, 2015 via Mylan Laboratories Limited subsidiary.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mylan Inc. / Famy Care Limited (women's healthcare businesses) (this deal) | 2015 | $800M | 56 |
| Mylan Inc. / Theravance Biopharma, Inc. (TD-4208 program) | 2015 | $265M | 61 |
| Mylan Inc. / Bioniche Pharma Holdings Limited | 2010 | $550M | 60 |
| Mylan Inc. / Agila Specialties (Strides Arcolab) | 2013 | $1.8B | 45 |
| Mylan Inc. / Abbott Laboratories (non-U.S. developed-markets specialty and branded generics business) | 2014 | $5.3B | 33 |
| Sumitovant Biopharma / Myovant Sciences Ltd. | 2022 | $1.7B | 60 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
← Browse all deals · How we score deals
More: 2015 deals · Mylan Inc. deals · Women's Health deals